Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
KEYVIBE-008
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
- NCT05224141 ↗
- Active, not recruiting
- Merck Sharp & Dohme LLC
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on KEYVIBE-008 (MK-7684A in first-line extensive-stage small cell lung cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on KEYVIBE-008 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 8 posts on X | |
| 1 YouTube video |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination With Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination With Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants With Extensive-Stage Small Cell Lung Cancer (KEYVIBE-008)
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Small Cell Lung Carcinoma
- Interventions
- Pembrolizumab/Vibostolimab Co-Formulation; Saline placebo; Etoposide; Cisplatin; Atezolizumab; Carboplatin
- Arms
- Pembrolizumab/Vibostolimab · Experimental
- Atezolizumab · Active comparator
- Enrollment
- 460
- Primary outcomes
- Overall Survival (OS)
- Sponsor
- Merck Sharp & Dohme LLC
- Start
- Mar 24, 2022
- Primary completion
- Jun 4, 2024
- Results posted
- Yes
- Registry record
- NCT05224141 · updated Jul 8, 2025
Publications
linked from the registry- Sands J, Lu S, Aerts JG, Reck M, Navarro A, Shentzer Kutiel T, Peled N, Casarini I, Kerr SJ, Takahashi T, Bilici A, Cheng Y, Wang M, Lee SY, Lowczak A, Mazieres J, Hu H, Wu J, Aggarwal H, El-Osta H, Paz-Ares L. Vibostolimab Coformulated with Pembrolizumab Plus Chemotherapy as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer. Target Oncol. 2026 Oct 20. doi: 10.1007/s11523-026-01237-w. Online ahead of print. PubMed 42900351
- Shapira-Frommer R, Niu J, Perets R, Peters S, Shouse G, Lugowska I, Garassino MC, Sands J, Keenan T, Zhao B, Healy J, Ahn MJ. The KEYVIBE program: vibostolimab and pembrolizumab for the treatment of advanced malignancies. Future Oncol. 2024;20(27):1983-1991. doi: 10.1080/14796694.2024.2343272. Epub 2024 Sep 4. PubMed 39230120